Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 6796 to 6810 of 8314 results

  1. Induction of labour in late intrauterine fetal death: vaginal misoprostol (after oral mifepristone) (ESUOM11)

    This evidence summary has been updated and replaced by NICE guideline NG207.

  2. Dapagliflozin for treating chronic kidney disease (TA775)

    This guidance has been updated and replaced by NICE technology appraisal guidance 1075.

  3. Psychosis and schizophrenia: management (CG82)

    This guidance has been updated and replaced by NICE guideline CG178. This guideline updates and replaces NICE guideline CG1.

  4. Insertion of a balloon device to disimpact an engaged fetal head before an emergency caesarean section (IPG515)

    This guidance has been updated and replaced by NICE interventional procedures guidance 800.

  5. SIR-Spheres for treating inoperable hepatocellular carcinoma (MIB63)

    This medtech innovation briefing has been updated and replaced by NICE technology appraisal guidance 688.

  6. The clinical effectiveness and cost effectiveness of newer atypical antipsychotic drugs for schizophrenia (TA43)

    This guidance has been updated and replaced by NICE guideline CG82.

  7. Pneumonia (hospital-acquired): antimicrobial prescribing (NG139)

    This guideline has been updated and replaced by NICE's guideline on pneumonia: diagnosis and management (NG250).

  8. Pneumonia (community-acquired): antimicrobial prescribing (NG138)

    This guideline has been updated and replaced by NICE's guideline on pneumonia in adults: diagnosis and management (NG250).

  9. Pneumonia in adults: diagnosis and management (CG191)

    This guideline has been updated and replaced by NICE's guideline on pneumonia: diagnosis and management (NG250).

  10. Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (TA611)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA1007.

  11. The clinical effectiveness and cost effectiveness of routine anti-D prophylaxis for RhD-negative women in pregnancy (TA41)

    This guidance has been updated and replaced by NICE technology appraisal guidance 156

  12. Ruxolitinib for treating polycythaemia vera (terminated appraisal) (TA356)

    This guidance has been updated and replaced by NICE technology appraisal guidance TA921.

  13. Adalimumab, etanercept and infliximab for ankylosing spondylitis (TA143)

    This guidance has been updated and replaced by NICE technology appraisal guidance 383.